Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Cooke

Allergy & Immunology Tavares, FL Medical Doctor

NPI 1477852689 CMS profile 547803

1822 Salk Ave, Tavares, FL 32778

Open in the dashboard

General payments

$16,780

643 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Cooke of Tavares, FL is reported in the CMS Open Payments database as having received $16,780 across 643 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,615 174
2024 General $3,041 129
2023 General $2,269 106
2022 General $3,646 110
2021 General $1,798 68
2020 General $894 40
2019 General $517 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Cooke
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Andrew Cooke were reported at $4,615. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Andrew Cooke Allergy & Immunology median Middle half National median
2019 $517 $594 $163–$1,512 $163
2020 $894 $426 $106–$1,233 $114
2021 $1,798 $638 $157–$1,708 $132
2022 $3,646 $790 $205–$1,961 $149
2023 $2,269 $852 $220–$2,147 $160
2024 $3,041 $865 $203–$2,267 $164
2025 $4,615 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $2,666 63 payments
  2. AstraZeneca Pharmaceuticals LP $2,272 94 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,290 71 payments
  4. GlaxoSmithKline, LLC. $1,232 71 payments
  5. Pharming Healthcare, Inc. $1,210 25 payments
  6. Regeneron Healthcare Solutions, Inc. $1,204 45 payments
  7. Pfizer Inc. $899 49 payments
  8. CSL Behring $755 32 payments
  9. Octapharma USA, Inc. $647 15 payments
  10. Amgen Inc. $582 16 payments
  11. Other $4,021 162 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,399 636 payments
  2. Consulting Fee $1,134 2 payments
  3. Education $246 5 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $3,859 114 payments
  2. RUCONEST $1,195 24 payments
  3. FASENRA $1,127 49 payments
  4. CUVITRU $1,034 54 payments
  5. DUPIXENT Inflammation And Immunology $728 32 payments
  6. CUTAQUIG $647 15 payments
  7. TRELEGY ELLIPTA $547 28 payments
  8. NUCALA $493 31 payments
  9. DUPIXENT Immunology And Inflammation $477 13 payments
  10. Xhance $450 20 payments
  11. Other $8,557 380 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,000

Median for Allergy/ Immunology: 449

Drug cost

$1,584,724

Median for Allergy/ Immunology: $169,700

Branded share of claims

49%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 33 $280,928
Dupixent Syringe Dupilumab Brand 63 $254,249
Dupixent Pen Dupilumab Brand 55 $247,730
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 291 $241,817
Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 Brand 39 $149,701
Tezspire Tezepelumab-Ekko Brand 16 $97,027
Cibinqo Abrocitinib Brand 14 $80,498
Adbry Tralokinumab-Ldrm Brand 18 $67,457
Xolair Omalizumab Brand 18 $50,674
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 41 $29,430

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$534,692

Medicare's payments for the services billed

Medicare patients

551

Average age 74

Services billed

42,862

368 women, 183 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 36%
COPD 30%
Chronic kidney disease 26%
Diabetes 23%
Depression 23%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $360
  • Regeneron Healthcare Solutions, Inc. $174
$534 118 —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $258
$258 39 —
RUCONEST
  • Pharming Healthcare, Inc. $204
$204 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $200
$200 — —
ACTIMMUNE
  • Amgen Inc. $168
$168 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

643 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record